Display options
Cite
Lo AK, Dawson CW, Lung HL, et al. The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy. Front Oncol. 2021;11:640207doi: 10.3389/fonc.2021.640207.
Lo, A. K., Dawson, C. W., Lung, H. L., Wong, K. L., & Young, L. S. (2021). The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy. Frontiers in oncology, 11640207. https://doi.org/10.3389/fonc.2021.640207
Lo, Angela Kwok-Fung, et al. "The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy." Frontiers in oncology vol. 11 (2021): 640207. doi: https://doi.org/10.3389/fonc.2021.640207
Lo AK, Dawson CW, Lung HL, Wong KL, Young LS. The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy. Front Oncol. 2021 Feb 25;11:640207. doi: 10.3389/fonc.2021.640207. eCollection 2021. PMID: 33718235; PMCID: PMC7947715.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2021 Feb 25;11:640207. doi: 10.3389/fonc.2021.640207. eCollection 2021.

The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy.

Frontiers in oncology

Angela Kwok-Fung Lo, Christopher W Dawson, Hong Lok Lung, Ka-Leung Wong, Lawrence S Young

Affiliations

  1. Department of Chemistry, Hong Kong Baptist University, Hong Kong, China.
  2. Warwick Medical School, University of Warwick, Coventry, United Kingdom.
  3. Department of Biology, Hong Kong Baptist University, Hong Kong, China.

PMID: 33718235 PMCID: PMC7947715 DOI: 10.3389/fonc.2021.640207

Abstract

Nasopharyngeal carcinoma (NPC) is closely associated with Epstein-Barr virus (EBV) infection. It is also characterized by heavy infiltration with non-malignant leucocytes. The EBV-encoded latent membrane protein 1 (LMP1) is believed to play an important role in NPC pathogenesis by virtue of its ability to activate multiple cell signaling pathways which collectively promote cell proliferation and survival, angiogenesis, invasiveness, and aerobic glycolysis. LMP1 also affects cell-cell interactions, antigen presentation, and cytokine and chemokine production. Here, we discuss how LMP1 modulates local immune responses that contribute to the establishment of the NPC tumor microenvironment. We also discuss strategies for targeting the LMP1 protein as a novel therapy for EBV-driven malignancies.

Copyright © 2021 Lo, Dawson, Lung, Wong and Young.

Keywords: Epstein-Barr virus; latent membrane protein 1; nasopharyngeal carcinoma; therapy; tumor microenvironment

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Front Oncol. 2019 Aug 06;9:713 - PubMed
  2. J Virol. 2002 Oct;76(20):10427-36 - PubMed
  3. Cancer Res. 2007 Mar 1;67(5):1970-8 - PubMed
  4. J Med Virol. 2002 Jan;66(1):63-9 - PubMed
  5. Cancer Invest. 2004;22(4):483-91 - PubMed
  6. Int J Cancer. 2017 Oct 15;141(8):1512-1521 - PubMed
  7. Head Neck. 2011 Jun;33(6):886-97 - PubMed
  8. Cancer Res. 2012 Mar 1;72(5):1116-25 - PubMed
  9. Cancer Res. 2017 Jul 1;77(13):3591-3604 - PubMed
  10. Chin Clin Oncol. 2016 Apr;5(2):23 - PubMed
  11. Oncotarget. 2015 Mar 30;6(9):7221-31 - PubMed
  12. Vaccines (Basel). 2016 Jun 24;4(3): - PubMed
  13. Clin Cancer Res. 2001 Jul;7(7):1946-51 - PubMed
  14. Sci Rep. 2019 Mar 13;9(1):4389 - PubMed
  15. Med Oncol. 2005;22(2):113-21 - PubMed
  16. Neoplasia. 2006 Mar;8(3):173-80 - PubMed
  17. J Cancer. 2017 Oct 23;8(18):3897-3902 - PubMed
  18. Lancet. 2019 Jul 6;394(10192):64-80 - PubMed
  19. Viruses. 2013 Jun 21;5(6):1587-606 - PubMed
  20. Oncogenesis. 2020 Jul 6;9(7):65 - PubMed
  21. Mol Ther. 2014 Feb;22(2):371-377 - PubMed
  22. Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6905-10 - PubMed
  23. J Gen Virol. 2008 Nov;89(Pt 11):2806-2820 - PubMed
  24. J Immunol. 2006 Oct 1;177(7):4897-906 - PubMed
  25. Am J Pathol. 2001 Jul;159(1):27-33 - PubMed
  26. Proc Natl Acad Sci U S A. 2019 Dec 10;: - PubMed
  27. J Virol. 2009 Nov;83(22):11734-45 - PubMed
  28. J Pathol. 2019 Apr;247(5):641-649 - PubMed
  29. J Leukoc Biol. 2001 May;69(5):779-84 - PubMed
  30. Semin Cancer Biol. 2008 Dec;18(6):388-96 - PubMed
  31. Semin Cancer Biol. 2012 Apr;22(2):144-53 - PubMed
  32. J Pathol. 2005 May;206(1):68-75 - PubMed
  33. PLoS Pathog. 2017 Jul 21;13(7):e1006503 - PubMed
  34. Head Neck Pathol. 2009 Dec;3(4):276-82 - PubMed
  35. Hum Pathol. 2004 Jun;35(6):722-8 - PubMed
  36. Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9 - PubMed
  37. J Pathol. 2015 Oct;237(2):238-48 - PubMed
  38. Exp Mol Med. 2015 Jan 23;47:e131 - PubMed
  39. J Virol. 2013 Aug;87(15):8606-23 - PubMed
  40. Cancer Res. 2011 Aug 15;71(16):5393-9 - PubMed
  41. Cell Res. 2020 Nov;30(11):950-965 - PubMed
  42. Clin Vaccine Immunol. 2014 Feb;21(2):256-9 - PubMed
  43. Semin Cancer Biol. 2012 Apr;22(2):127-36 - PubMed
  44. Blood. 2003 Apr 15;101(8):3150-6 - PubMed
  45. Mol Cancer Ther. 2012 Mar;11(3):594-603 - PubMed
  46. Oncotarget. 2015 Oct 6;6(30):29311-23 - PubMed
  47. Curr Treat Options Oncol. 2013 Jun;14(2):224-36 - PubMed
  48. J Immunol. 2000 Jul 15;165(2):663-70 - PubMed
  49. Chin J Cancer. 2014 Dec;33(12):581-90 - PubMed
  50. Expert Rev Mol Med. 2015 Aug 18;17:e15 - PubMed
  51. Cancer. 2000 Aug 15;89(4):715-23 - PubMed
  52. Lancet Oncol. 2018 Oct;19(10):1338-1350 - PubMed
  53. Cancer Immunol Immunother. 2019 Aug;68(8):1317-1329 - PubMed
  54. Cancer Lett. 2021 Jan 28;497:178-189 - PubMed
  55. J Virol. 2010 Jan;84(1):407-17 - PubMed
  56. J Exp Med. 2014 May 5;211(5):781-90 - PubMed
  57. Biomed Res Int. 2014;2014:507353 - PubMed
  58. J Clin Invest. 2013 Dec;123(12):5269-83 - PubMed
  59. PLoS One. 2007 Nov 07;2(11):e1122 - PubMed
  60. Oncogene. 2014 Apr 17;33(16):2098-109 - PubMed
  61. Biochem Biophys Res Commun. 2012 Jul 27;424(2):251-6 - PubMed
  62. Cell Adh Migr. 2012 May-Jun;6(3):231-5 - PubMed
  63. Ann Oncol. 2012 Apr;23(4):997-1005 - PubMed
  64. J Virol. 2004 Dec;78(23):12987-95 - PubMed
  65. Nat Rev Cancer. 2004 Oct;4(10):757-68 - PubMed
  66. Nat Immunol. 2005 Dec;6(12):1245-52 - PubMed
  67. Cell Mol Immunol. 2007 Oct;4(5):329-35 - PubMed
  68. J Virol. 2003 Sep;77(17):9359-68 - PubMed
  69. Genes Immun. 2011 Sep;12(6):399-414 - PubMed
  70. Nat Commun. 2017 Jan 18;8:14121 - PubMed
  71. Cancer Lett. 2013 Apr 28;330(2):141-9 - PubMed
  72. Cancer Res. 2004 Feb 15;64(4):1483-9 - PubMed
  73. Mol Cancer. 2010 Jun 18;9:155 - PubMed
  74. Expert Opin Biol Ther. 2008 Sep;8(9):1265-94 - PubMed
  75. Cancers (Basel). 2018 Mar 21;10(4): - PubMed
  76. Clin Cancer Res. 2007 Sep 1;13(17):4993-5000 - PubMed
  77. J Hematol Oncol. 2019 Aug 28;12(1):86 - PubMed
  78. Cancer Cell. 2004 May;5(5):423-8 - PubMed
  79. Cancer Res. 2010 Dec 15;70(24):10161-9 - PubMed
  80. Oncotarget. 2016 Mar 29;7(13):16910-22 - PubMed
  81. Annu Rev Immunol. 2015;33:787-821 - PubMed
  82. Nat Rev Cancer. 2020 Mar;20(3):174-186 - PubMed
  83. Int J Cancer. 1997 Jul 29;72(3):398-402 - PubMed
  84. J Clin Oncol. 2014 Mar 10;32(8):798-808 - PubMed
  85. J Clin Oncol. 2018 May 10;36(14):1412-1418 - PubMed
  86. Oncotarget. 2014 Dec 15;5(23):12189-202 - PubMed
  87. Am J Pathol. 2008 Jul;173(1):195-204 - PubMed
  88. Oncotarget. 2016 Aug 16;7(33):53217-53229 - PubMed
  89. Immunol Cell Biol. 2007 Jul;85(5):370-7 - PubMed
  90. J Med Virol. 2011 Apr;83(4):665-78 - PubMed
  91. Eur J Cancer. 1995;31A(5):658-60 - PubMed
  92. Haematologica. 2010 Oct;95(10):1769-77 - PubMed
  93. Int J Cancer. 2020 Apr 15;146(8):2305-2314 - PubMed
  94. Cancer Commun (Lond). 2020 Jan;40(1):60-62 - PubMed
  95. Head Neck Pathol. 2017 Mar;11(1):16-22 - PubMed
  96. Oncotarget. 2017 Apr 4;8(14):23479-23491 - PubMed
  97. Oncotarget. 2016 Nov 8;7(45):74393-74409 - PubMed
  98. Nat Rev Cancer. 2016 Dec;16(12):789-802 - PubMed
  99. Cancer Gene Ther. 2005 Jul;12(7):647-54 - PubMed
  100. Elife. 2015 Aug 11;4: - PubMed
  101. J Clin Oncol. 2017 Dec 20;35(36):4050-4056 - PubMed
  102. J Transl Med. 2010 Mar 26;8:30 - PubMed
  103. Clin Cancer Res. 2008 Nov 1;14(21):6979-87 - PubMed
  104. J Virol. 2005 Nov;79(21):13326-37 - PubMed
  105. J Biosci. 2016 Sep;41(3):507-34 - PubMed
  106. Br J Cancer. 2007 Feb 26;96(4):617-22 - PubMed
  107. Int J Cancer. 1994 Apr 15;57(2):240-4 - PubMed
  108. J Immunol. 2003 Jun 15;170(12):6183-9 - PubMed
  109. Genes Immun. 2011 Apr;12(3):157-68 - PubMed
  110. Mol Cancer. 2011 Feb 03;10(1):11 - PubMed
  111. J Clin Oncol. 2005 Dec 10;23(35):8942-9 - PubMed
  112. Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20370-5 - PubMed
  113. Cancer Lett. 2018 Dec 1;438:52-62 - PubMed
  114. J Natl Cancer Inst. 2014 Dec 12;107(1):363 - PubMed
  115. J Cancer Res Clin Oncol. 2012 Jan;138(1):57-64 - PubMed
  116. Med Oncol. 2011 Dec;28 Suppl 1:S326-32 - PubMed
  117. Mol Ther. 2014 Jan;22(1):132-9 - PubMed
  118. Acta Otolaryngol. 2017 Aug;137(8):888-894 - PubMed
  119. Mol Cancer Ther. 2008 Jun;7(6):1430-9 - PubMed
  120. Virology. 2001 Feb 15;280(2):183-98 - PubMed
  121. Sci Transl Med. 2019 Mar 6;11(482): - PubMed
  122. Int J Oncol. 2014 May;44(5):1551-60 - PubMed
  123. Blood. 2003 Mar 1;101(5):1905-12 - PubMed
  124. Curr Top Microbiol Immunol. 2015;391:325-53 - PubMed
  125. Pathol Int. 2017 Sep;67(9):461-466 - PubMed
  126. Oncogene. 2014 Sep 11;33(37):4613-22 - PubMed
  127. Oncoimmunology. 2015 Jun 1;4(12):e1052935 - PubMed
  128. BMC Cancer. 2006 Dec 08;6:283 - PubMed
  129. Int J Cancer. 2007 Oct 1;121(7):1494-506 - PubMed
  130. Cancer Lett. 2020 May 28;478:93-106 - PubMed
  131. J Virol. 2017 Feb 14;91(5): - PubMed
  132. Oncotarget. 2017 Nov 18;8(64):107452-107461 - PubMed
  133. J Biol Chem. 2004 Oct 29;279(44):46335-42 - PubMed
  134. Int Immunopharmacol. 2020 Nov;88:106939 - PubMed
  135. Virology. 2010 Sep 30;405(2):464-73 - PubMed
  136. Oral Oncol. 2020 May;104:104616 - PubMed
  137. Blood. 2009 Feb 26;113(9):1957-66 - PubMed
  138. Eur J Immunol. 2006 Mar;36(3):593-602 - PubMed
  139. J Immunol Res. 2016;2016:1720827 - PubMed

Publication Types